Institutional investors hold a majority ownership of IMGN through the 90.65% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended September 2015, these large investors purchased a net $865.7 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
ORBIMED ADVISORS LLC Bought 2.6 Million shares of ImmunoGen Inc
BAKER BROS. ADVISORS LP Bought 1.2 Million shares of ImmunoGen Inc
D. E. SHAW & CO. LP Bought 478.4 Thousand shares of ImmunoGen Inc